– The company to present important new data from two Phase I trials of its leading molecule, AHB-137, aimed at achieving a functional cure for chronic hepatitis B, in two late-breaker posters. SAN FRANCISCO, May 28, 2024 /PRNewswire/ — AusperBio Therapeutics, Inc. and Ausper Biopharma Co….
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.